Balkan Journal of Medical Genetics

EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION STATUS AND THE IMPACT ON CLINICAL OUTCOMES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER
Huang HM1, Wei Y1, Wang JJ1, Ran FY1, Wen Y2, Chen QH3, Zhang BF1,*
*Corresponding Author: Dr. Bingfei Zhang, Sinopharm Dongfeng General Hospital, Hubei University of Medicine, No. 16 Daling Road, 442008, Shiyan, Hubei, China. Tel.: + 86-29-8272597, Email: dfzyysszx@163.com
page: 29

INTRODUCTION

Lung cancer is the major cause of cancer-related death in the world. As reported by American Cancer Society, lung cancer caused more deaths than breast, prostate, colorectal, and brain cancers combined in 2017 [1]. Nonsmall cell lung cancer (NSCLC) consists of about 85% of all lung cancers and is usually diagnosed at advanced or metastatic stage [2]. Platinum-based regimens have been the mainly conventional chemotherapy for advanced NSCLC treatment with a poor benefit in survival. In the past decade, an increased understanding of the signaling pathways contributed to the development of target agents, and the addition of target therapy to the treatment protocols for NSCLC patients was a major breakthrough and had obtained clinically significant survival benefit [3]. The epidermal growth factor receptor (EGFR) mutations are predictive markers for response to target therapy in NSCLC patients [4]. EGFR is a transmembrane glycoprotein existing on the cell surface and plays an important role in tumor cell survival and proliferation. Tyrosine kinase inhibitors (TKIs) that specifically target EGFR have been used as first-line treatment in EGFR mutation-positive patients [5, 6]. Lindeman et al. [6] reported that the response to TKIs was approximately 68% in patients with activating EGFR mutations, while there was only an 11% response rate in patients with wild type EGFR. Given the benefit of EGFR-TKI therapy, EGFR mutation testing was recommended to NSCLC patients before initiation of firstline therapy, according to clinical practice guidelines [7]. The genetic divergence of EGFR mutations according to ethnicity has been reported. Asian populations have the highest EGFR mutation frequency and it has become very common in clinical practice in some Asian countries to treat patients based on their EGFR status [8, 9]. However, most of the studies conducted on EGFR mutations in Asia were carried out in Korea or Japan, data available on EGFR mutations in China are limited. The present study was to evaluate the EGFR mutation status in Chinese NSCLC patients (Stage I-IV), explore its association with clinical characteristics, and further investigate differences in prognosis between advanced NSCLC patients (Stage IIIB-IV) with and without EGFR mutations.

Number 27 VOL. 27 (2), 2024	Number 27 VOL. 27 (1), 2024
Number 26 Number 26 VOL. 26(2), 2023 All in one	Number 26 VOL. 26(2), 2023
Number 26 VOL. 26, 2023 Supplement	Number 26 VOL. 26(1), 2023
Number 25 VOL. 25(2), 2022	Number 25 VOL. 25 (1), 2022
Number 24 VOL. 24(2), 2021	Number 24 VOL. 24(1), 2021
Number 23 VOL. 23(2), 2020	Number 22 VOL. 22(2), 2019
Number 22 VOL. 22(1), 2019	Number 22 VOL. 22, 2019 Supplement
Number 21 VOL. 21(2), 2018	Number 21 VOL. 21 (1), 2018
Number 21 VOL. 21, 2018 Supplement	Number 20 VOL. 20 (2), 2017
Number 20 VOL. 20 (1), 2017	Number 19 VOL. 19 (2), 2016
Number 19 VOL. 19 (1), 2016	Number 18 VOL. 18 (2), 2015
Number 18 VOL. 18 (1), 2015	Number 17 VOL. 17 (2), 2014
Number 17 VOL. 17 (1), 2014	Number 16 VOL. 16 (2), 2013
Number 16 VOL. 16 (1), 2013	Number 15 VOL. 15 (2), 2012
Number 15 VOL. 15, 2012 Supplement	Number 15 Vol. 15 (1), 2012
Number 14 14 - Vol. 14 (2), 2011	Number 14 The 9th Balkan Congress of Medical Genetics
Number 14 14 - Vol. 14 (1), 2011	Number 13 Vol. 13 (2), 2010
Number 13 Vol.13 (1), 2010	Number 12 Vol.12 (2), 2009
Number 12 Vol.12 (1), 2009	Number 11 Vol.11 (2),2008
Number 11 Vol.11 (1),2008	Number 10 Vol.10 (2), 2007
Number 10 10 (1),2007	Number 9 1&2, 2006
Number 9 3&4, 2006	Number 8 1&2, 2005
Number 8 3&4, 2004	Number 7 1&2, 2004
Number 6 3&4, 2003	Number 6 1&2, 2003
Number 5 3&4, 2002	Number 5 1&2, 2002
Number 4 Vol.3 (4), 2000	Number 4 Vol.2 (4), 1999
Number 4 Vol.1 (4), 1998	Number 4 3&4, 2001
Number 4 1&2, 2001	Number 3 Vol.3 (3), 2000
Number 3 Vol.2 (3), 1999	Number 3 Vol.1 (3), 1998
Number 2 Vol.3(2), 2000	Number 2 Vol.1 (2), 1998
Number 2 Vol.2 (2), 1999	Number 1 Vol.3 (1), 2000
Number 1 Vol.2 (1), 1999	Number 1 Vol.1 (1), 1998

About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact